Skip links

Phase I dose escalation study to evaluate the safety and side effects of 225Ac-PSMA in patients with metastatic prostate cancer

Project summary

Radionuclides are radioactive particles that can irradiate cancer specifically from within. This is promising for prostate cancer, but research into safety and effectiveness is needed before the treatment can make a definitive appearance.
The aim of this study is to determine the safety and side effects of 225Ac-PSMA therapy in patients with metastatic prostate cancer.


This new, promising treatment can prolong life and reduce pain in patients with metastases. This will also improve the quality of life, which is very important for patients in their final phase of life. In addition, it is important to first determine how the treatment can be given both effectively and safely. This project makes an important contribution to this.

More detailed information

Principal Investigator:

Dr. Tessa Brabander

Role Erasmus MC:



Project website:

Funding Agency:

KWF Kankerbestrijding